Two-Year Outcome of a Combination of Weight Loss Therapies for Type 2 Diabetes

Redmon, J. Bruce; Reck, Kristell P.; Raatz, Susan K.; Swanson, Joyce E.; Kwong, Christine A.; Ji, Hong; Thomas, William; Bantle, John P.
June 2005
Diabetes Care;Jun2005, Vol. 28 Issue 6, p1311
Academic Journal
OBJECTIVE -- To evaluate the effects over 2 years of a weight loss program combining several weight loss strategies on weight loss and diabetes control in overweight subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS -- A total of 59 overweight or obese individuals with type 2 diabetes were randomly assigned to either a combination therapy weight loss program for 2 years (C therapy) or a standard therapy weight loss program for 1 year followed by a combination therapy weight loss program in the 2nd year (S/C therapy). C therapy combined the use of meal replacement products, repetitive intermittent low-calorie-diet weeks, and pharmacologic therapy with sibutramine. Outcome measures included changes in weight, glycemic control, plasma lipids, blood pressure, and body composition over 2 years. RESULTS -- A total of 48 participants (23 in the C therapy group and 25 in the S/C therapy group) completed 2 years of study. After 2 years, the C therapy' group had weight loss of 4.6 ± 1.2 kg (P < 0.001) and a decrease in HbA1c of 0.5 ± 0.3% (P = 0.08) from baseline. At 2 years, the C therapy group had significant reductions in BMI, fat mass, lean body mass, and systolic blood pressure. The S/C therapy group showed changes in weight and HbA1c in year 2 of the study that were similar to those demonstrated by the C therapy group in year 1. CONCLUSIONS -- This combination weight loss program resulted in significant weight loss and improved diabetes control over a 2-year period in overweight subjects with type 2 diabetes.


Related Articles

  • Evaluation of Glycemic Parameters in Obese Diabetic Patients Treated with Phentermine and Topiramate: Outcomes in a Private Practice Setting. Najarian, Thomas; Rowsemitt, Carol N.; Charbonneau, Vicki U.; Peterson, Craig A. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA560 

    Effective and well-tolerated treatments are needed for obese patients with type 2 diabetes. Low-dose combinations of phentermine and topiramate (P/T) have demonstrated significant weight loss in a controlled trial using a proprietary formulation, and have been used for the treatment of obesity...

  • The DIAMOND system in the treatment of type 2 diabetes mellitus in an obese patient. Kozakowski, Jarosław; Lebovitz, Harold E.; Kiciak, Adam; Zgliczyński, Wojciech; Tarnowski, Wiesław // Videosurgery & Other Miniinvasive Techniques / Wideochirurgia i;Dec2014, Vol. 9 Issue 4, p627 

    Obesity and type 2 diabetes mellitus have reached epidemic proportions worldwide. As the majority of antidiabetic medications are of limited efficacy and patient adherence to long-term therapy is one of the main limiting factors of effective blood glucose and body weight control, new therapies...

  • Low-Carb Improvements. Karl, E. // Diabetes Health;Sep2005, Vol. 14 Issue 9, p32 

    Discusses research being done on the benefits of a low-carbohydrate diet to obese people with type 2 diabetes. Reference to a study published in the March 2005 issue of "Annals of Internal Medicine" journal; Details of the diet assigned to the patients involved in the study; Recorded weight...

  • Rimonabant: An Answer to Overweight in Diabetes? Kuritzky, Louis // Travel Medicine Advisor;Feb2007, Vol. 17 Issue 2, Special section p3 

    The article discusses research being done on the impact of Rimonabant (RBT) on overweight diabetic subjects with reference to a study conducted by A. J. Scheen et al, published in a 2006 issue of "Lancet." According to the article, the use of RBT resulted to weight loss in non-diabetic...

  • Call for more gastric banding for type 2 diabetes.  // British Journal of Hospital Medicine (17508460);Jul2009, Vol. 70 Issue 7, p377 

    The article reports on the call for greater consideration of gastric banding as an option for obese people with type 2 diabetes in Great Britain. It mentions that the gastric banding procedure is a highly effective option for selected obese patients who fail to reduce their weight through...

  • Determinants of the Resolution of Type 2 Diabetes After Bariatric Surgery. Zalesin, Kerstyn C.; Krause, Kevin R.; Chengelis, David L.; McCullough, Peter A. // Vascular Disease Prevention;May2008, Vol. 5 Issue 2, p75 

    Background: The association between body mass index (BMI) and the development of type 2 diabetes (T2DM) is well established. The determinants of the resolution of T2DM with weight reduction after bariatric surgery, however, are not fully understood. Objective: Examine the course of T2DM during...

  • Key Global Literature. Fonseca, Vivian // Diabetes Care;Sep2005, Vol. 28 Issue 9, p2339 

    Provides information on a randomized study of orlistat in combination with a weight management program in obese patients with type 2 diabetes treated with metformin. Comparison between orlistat treatment and placebo; Impact of orlistaton glycemic control and the lipid profile in type 2 diabetes.

  • Amphetamine-Like Analogues in Diabetes: Speeding towards Ketogenesis. Branis, Natalia M.; Wittlin, Steven D. // Case Reports in Endocrinology;4/19/2015, Vol. 2015, p1 

    Obesity is common in patients with type 1 and type 2 diabetes. Amphetamine-like analogues comprise the most popular class of weight loss medications. We present a case of a 34-year-old African American female with a history of type 1 diabetes, dyslipidemia, and obesity who developed diabetic...

  • Progressive Reduction in Body Weight with Pramlintide Therapy in Obese Subjects with Type 2 Diabetes Treated with Diet and Exercise and/or Metformin. Edelman, Steve; Lush, Cameron; Kesty, Nicole; Burns, Colleen; Weyer, Christian; Frias, Juan // Diabetes;Jun2007 Supplement 1, Vol. 56, pA461 

    Pramlintide (PRAM), an analog of the β-cell hormone amylin, has several clinical effects relevant to obesity, including meal-related satiation, reduced food intake, and weight loss. We previously reported that 16-wk PRAM treatment resulted in a placebo (PBO)-corrected change in body weight...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics